A triple dose of Novo Nordisk's GLP-1 agonist Wegovy has shown improved activity on weight loss in an obesity trial, as the drugmaker tries to fend off a marketplace challenge from Eli Lilly. A 7.2mg ...

XOP has a poor 10-year performance track record and a high expense fee of 0.35%. Click here to read more about XOP ETF and ...